About MediSieve
MediSieve is a company based in London (United Kingdom) founded in 2014 by George Frodsham.. MediSieve has raised $4.18 million across 5 funding rounds from investors including UK Research and Innovation, European Union and 24 Haymarket. The company has 12 employees as of September 30, 2021. MediSieve offers products and services including MediSieve System, AAV Gene Therapy Enabler, IL-6 Driven Hyperinflammation Treatment, and Severe Malaria Treatment. MediSieve operates in a competitive market with competitors including Haemonetics, Vetex Medical, Immutrix Therapeutics, Hemostasis and Immunocept Medical Products, among others.
- Headquarter London, United Kingdom
- Employees 12 as on 30 Sep, 2021
- Founders George Frodsham
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Medisieve Ltd
- Date of Incorporation 08 Apr, 2014
- Jurisdiction LONDON, ENGLAND
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$4.18 M (USD)
in 5 rounds
-
Latest Funding Round
$2.14 M (USD), Series A
Jun 23, 2021
-
Investors
UK Research and Innovation
& 3 more
-
Employee Count
12
as on Sep 30, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of MediSieve
MediSieve offers a comprehensive portfolio of products and services, including MediSieve System, AAV Gene Therapy Enabler, IL-6 Driven Hyperinflammation Treatment, and Severe Malaria Treatment. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Purifies blood by removing pathogens with magnetic beads.
Depletes antibodies to facilitate novel gene therapies.
Treats hyperinflammation by depleting specific cytokines.
Removes infected cells to manage severe malaria cases.
Unlock access to complete
Unlock access to complete
Funding Insights of MediSieve
MediSieve has successfully raised a total of $4.18M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $2.14 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series A — $2.1M
-
First Round
First Round
(01 Jan 2017)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2021 | Amount | Series A - MediSieve | Valuation | 24 Haymarket |
|
| Jun, 2021 | Amount | Grant - MediSieve | Valuation |
investors |
|
| Jun, 2018 | Amount | Seed - MediSieve | Valuation | 24 Haymarket |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in MediSieve
MediSieve has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include UK Research and Innovation, European Union and 24 Haymarket. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Tech focused VC firm investing in the UK
|
Founded Year | Domain | Location | |
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Founded Year | Domain | Location | |
|
Research and innovation funding is managed for UK advancement.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by MediSieve
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - MediSieve
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Medisieve Comparisons
Competitors of MediSieve
MediSieve operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Haemonetics, Vetex Medical, Immutrix Therapeutics, Hemostasis and Immunocept Medical Products, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Hematology products and solutions are provided for medical applications.
|
|
| domain | founded_year | HQ Location |
Catheters for venous clot management and removal are developed.
|
|
| domain | founded_year | HQ Location |
Blood cleansing treatment device
|
|
| domain | founded_year | HQ Location |
Develops and manufactures hemostatic products for surgical bleeding control and patient care.
|
|
| domain | founded_year | HQ Location |
Blood filtration therapy for severe sepsis is developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Medisieve
Frequently Asked Questions about MediSieve
When was MediSieve founded?
MediSieve was founded in 2014 and raised its 1st funding round 3 years after it was founded.
Where is MediSieve located?
MediSieve is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Who is the current CEO of MediSieve?
George Frodsham is the current CEO of MediSieve. They have also founded this company.
Is MediSieve a funded company?
MediSieve is a funded company, having raised a total of $4.18M across 5 funding rounds to date. The company's 1st funding round was a Seed of $2.04M, raised on Jan 01, 2017.
How many employees does MediSieve have?
As of Sep 30, 2021, the latest employee count at MediSieve is 12.
What does MediSieve do?
MediSieve was founded in 2014 in London, United Kingdom, and operates in the biotechnology sector. Magnetic blood filtration solutions are developed by the company to remove infected cells, pathogens, toxins, and viruses from blood. The Medisieve device integrates peristaltic haemofiltration pumps with antibody-coated magnetic particles, targeting specific cells or antigens for treating blood-borne diseases. Operations focus on therapeutic applications in healthcare.
Who are the top competitors of MediSieve?
MediSieve's top competitors include Haemonetics, Vetex Medical and Immutrix Therapeutics.
What products or services does MediSieve offer?
MediSieve offers MediSieve System, AAV Gene Therapy Enabler, IL-6 Driven Hyperinflammation Treatment, and Severe Malaria Treatment.
Who are MediSieve's investors?
MediSieve has 4 investors. Key investors include UK Research and Innovation, European Union, 24 Haymarket, and EIC Fund.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.